ENESDENewsletter →
Shotlee
Get the app
📖Complete Guide✅Updated 2026🔬Evidence-Based

Foundayo (Orforglipron) Guide

Eli Lilly's Oral GLP-1 Weight Loss Pill

Complete guide to Foundayo (orforglipron) — the first oral non-peptide GLP-1 pill for weight loss from Eli Lilly.

Download on theApp Store
Get it onGoogle Play
ATTAIN-1 (72 weeks)
Up to 27.3 lbs
Average weight reduction in adults without type 2 diabetes in the Phase 3 ATTAIN-1 obesity trial.
Phase 2 Weight Loss
~14.7%
Body weight reduction at 36 weeks in the Phase 2 obesity trial (Wharton et al., NEJM 2023).
HbA1c Reduction
Up to 2.1%
Hemoglobin A1c reduction in Phase 3 ACHIEVE trials for type 2 diabetes.
Dashboard
Your complete health overview in one place
🔥
14-day streak
Logged 18 of 18 scheduled shots
Next Shot Reminder
⌄
ACTIVE MEDICATIONS
FoundayoB12
FOUNDAYO
🔥 14
2
days away
Thursday · 7.5mg
⌄
Medication Supply
Foundayo
6.2 / 10 mg · Vial
~42 days left · Mar 15
B12
4.4 / 5 ml · Vial
~88 days left · May 8
Retatrutide
1.2 / 5 mg · Vial
~6 days left · refill soon
Medication Level Predictor
Estimated serum level & future decay
~5 days
Half-Life
7 Days2 Weeks1 Month90 Days
CURRENT LEVEL
5.42mg
Mar 6
● Today
ACTIVE MEDICATIONS
FoundayoRetatrutide
TODAY5.42 mgFeb 14Feb 22Mar 14
0mg2.7mg5.42mg (Peak)
18
Total Injections
💉 All time
122/78
Average BP
🩺 mmHg
8.4
Avg Mood
😊 /10
Health Chart
1mAll
218.6lb
↓ 8.4 lb · 3.7%
WeightInjectionsBPMood
2282222162102277.5mg7.5mg4mg10mg218
Feb 6Feb 14Feb 22Mar 2Today
Photos
12 photos · 2w streak
Week 1
Week 7
Today
Scheduled Reminders
Weight
Due today
Mood
Done
Blood Pressure
Tomorrow
Body Measurements
In 3 days
Dashboard
Your complete health overview in one place
🔥
14-day streak
Logged 18 of 18 scheduled shots
Next Shot Reminder
⌄
ACTIVE MEDICATIONS
FoundayoB12
FOUNDAYO
🔥 14
2
days away
Thursday · 7.5mg
⌄
Medication Supply
Foundayo
6.2 / 10 mg · Vial
~42 days left · Mar 15
B12
4.4 / 5 ml · Vial
~88 days left · May 8
Retatrutide
1.2 / 5 mg · Vial
~6 days left · refill soon
Medication Level Predictor
Estimated serum level & future decay
~5 days
Half-Life
7 Days2 Weeks1 Month90 Days
CURRENT LEVEL
5.42mg
Mar 6
● Today
ACTIVE MEDICATIONS
FoundayoRetatrutide
TODAY5.42 mgFeb 14Feb 22Mar 14
0mg2.7mg5.42mg (Peak)
18
Total Injections
💉 All time
122/78
Average BP
🩺 mmHg
8.4
Avg Mood
😊 /10
Health Chart
1mAll
218.6lb
↓ 8.4 lb · 3.7%
WeightInjectionsBPMood
2282222162102277.5mg7.5mg4mg10mg218
Feb 6Feb 14Feb 22Mar 2Today
Photos
12 photos · 2w streak
Week 1
Week 7
Today
Scheduled Reminders
Weight
Due today
Mood
Done
Blood Pressure
Tomorrow
Body Measurements
In 3 days
01BACKGROUND

What Is Foundayo (Orforglipron)?

Foundayo is the brand name for orforglipron (LY3502970), Eli Lilly's oral non-peptide GLP-1 receptor agonist developed for weight management and type 2 diabetes. Unlike injectable GLP-1 medications like Wegovy or Ozempic, Foundayo is a small molecule pill taken once daily.

What makes Foundayo unique: It's a non-peptide compound, meaning it doesn't break down in the digestive system like peptide-based drugs. This allows it to be taken with food at any time of day — no fasting, no timing restrictions, and no injections.

Foundayo represents a major shift in GLP-1 therapy. While Rybelsus (oral semaglutide) exists, it requires strict 30-minute fasting and has lower bioavailability. Foundayo eliminates these restrictions entirely, potentially improving real-world adherence and outcomes.

02KEY NUMBERS

Clinical Trial Results

📈
ATTAIN-1 (72 weeks)
0.0lbs
Average weight reduction in adults without type 2 diabetes in the Phase 3 ATTAIN-1 obesity trial.
💪
Phase 2 Weight Loss
0.0%
Body weight reduction at 36 weeks in the Phase 2 obesity trial (Wharton et al., NEJM 2023).
🏆
HbA1c Reduction
0.0%
Hemoglobin A1c reduction in Phase 3 ACHIEVE trials for type 2 diabetes.
03MECHANICS

How Foundayo Works

1
Activates GLP-1 receptors in the brain to reduce appetite and cravings
2
Slows gastric emptying to prolong feelings of fullness after meals
3
Enhances glucose-dependent insulin secretion for better blood sugar control
4
Small molecule structure survives stomach acid without special formulation
5
Absorbs effectively regardless of food intake — no fasting required
6
Maintains consistent blood levels with once-daily oral dosing
04DOSING

Expected Dosing Schedule

Week 1-2
3 mg daily

Starting dose

Week 3-4
6 mg daily

First escalation

Week 5-8
12-24 mg daily

Titration phase

Maintenance
36-45 mg daily

Target dose

05WHAT TO TRACK

Foundayo vs Injectable GLP-1s

01
💊
Oral Convenience
Once-daily pill taken with or without food. No needles, no refrigeration, no injection site rotation. Ideal for needle-phobic patients.
02
🔬
Non-Peptide Structure
Unlike Rybelsus (oral semaglutide), Foundayo's small molecule design means no fasting requirement and better absorption flexibility.
03
🏭
Easier Manufacturing
Small molecules are cheaper and faster to produce than biologic peptides, potentially reducing drug shortages and lowering costs.
04
🌍
Global Access Potential
No cold chain storage required for pills. Easier worldwide distribution including developing markets where refrigeration is limited.
06WHAT TO TRACK

Who Is Foundayo Best For?

01
✅
Ideal Candidates
Needle-phobic patients. Those who struggled with Rybelsus fasting restrictions. People with irregular schedules. Patients starting GLP-1 therapy for the first time. Those who prefer daily pills over weekly injections.
02
⚠️
Consider Alternatives If
You need maximum weight loss (injectable tirzepatide may be stronger). You prefer weekly dosing over daily pills. You respond well to current injectable GLP-1s. You want dual GIP/GLP-1 agonist effects (tirzepatide).
07WHAT TO TRACK

Side Effects

01
🔬
Common (Similar to All GLP-1s)
Nausea (most common, especially during dose escalation). Vomiting. Diarrhea. Constipation. Decreased appetite. These typically improve over time and with slower dose titration.
02
📊
Clinical Trial Observations
Side effect profile similar to injectable GLP-1s. GI effects typically mild to moderate in severity. Improved significantly with gradual dose escalation. No unexpected safety signals in Phase 3 data. Well-tolerated overall in ATTAIN and ACHIEVE trials.
08TIMELINE

Development Timeline

2023:
Phase 2 results published in NEJM showing ~14.7% weight loss at 36 weeks
2025:
Positive Phase 3 ATTAIN (obesity) and ACHIEVE (T2D) trial readouts reported
Late 2025:
Eli Lilly announces "Foundayo" as the brand name for orforglipron
2026:
Regulatory submissions to FDA for obesity and type 2 diabetes indications
Expected 2026-2027:
Potential FDA approval and commercial launch
09WHAT TO TRACK

Frequently Asked Questions

01
💊
Is Foundayo the same as orforglipron?
Yes. Foundayo is the brand name chosen by Eli Lilly for orforglipron (LY3502970). They are the same compound — a non-peptide oral GLP-1 receptor agonist.
02
🔬
Is Foundayo as effective as Ozempic?
Phase 3 ATTAIN-1 data shows meaningful weight loss. Direct cross-drug comparisons depend on study population and dose, but oral convenience is a major advantage for adherence.
03
🍽️
Can I really take it with food?
Yes. Unlike Rybelsus, Foundayo's small molecule structure allows absorption regardless of food intake. Take it with any meal or without food — no restrictions.
04
⏰
Why daily instead of weekly?
Small molecules are cleared faster than peptides. Daily dosing with zero restrictions may be preferable to weekly injections or weekly pills with strict fasting rules.
10FAQ

Guide FAQs

Foundayo is the brand name for orforglipron, Eli Lilly's oral non-peptide GLP-1 receptor agonist. It is a once-daily pill for weight loss and type 2 diabetes that does not require injections or fasting.

As of April 2026, Foundayo has completed Phase 3 trials and Eli Lilly has submitted regulatory filings. FDA approval is anticipated in 2026-2027.

Yes. Shotlee supports tracking Foundayo (orforglipron) doses, side effects, weight, and health metrics. It is free to use.

Free · Always

Track Your Foundayo Protocol in Shotlee

Free dose logging, side effect tracking, and health metric monitoring for your complete Foundayo (orforglipron) protocol.

Download on theApp Store
Get it onGoogle Play

📚References & sources

From the blog

Latest on Foundayo

Eli Lilly's Foundayo: A New Daily Pill Outperforming Oral Semaglutide
Health & Wellness

Eli Lilly's Foundayo: A New Daily Pill Outperforming Oral Semaglutide

A groundbreaking Phase 3 trial reveals that Eli Lilly's new daily oral medication, orforglipron (Foundayo), demonstrates superior efficacy in lowering blood sugar and promoting weight loss compared to existing oral semaglutide treatments for individuals with Type 2 diabetes. This development marks a significant step forward in non-injectable peptide therapies for metabolic health.

6 min read
Eli Lilly's $4.5 Billion Expansion: Fueling the Future of Weight Loss & Health
Health & Wellness

Eli Lilly's $4.5 Billion Expansion: Fueling the Future of Weight Loss & Health

Eli Lilly's monumental $4.5 billion investment in its Indiana facilities signals a significant ramp-up in production for groundbreaking GLP-1 agonists like Mounjaro and Zepbound, alongside future weight loss and cardiometabolic disease treatments. This expansion is poised to meet surging global demand and solidify Lilly's position at the forefront of pharmaceutical innovation.

6 min read
Eli Lilly's Oral GLP-1: A Strong Start Amidst Weight Loss Drug Hype
Weight Management

Eli Lilly's Oral GLP-1: A Strong Start Amidst Weight Loss Drug Hype

Eli Lilly's groundbreaking oral GLP-1, Foundayo, is demonstrating a promising launch, exceeding initial expectations and hinting at a significant expansion of the weight loss and diabetes management market. Discover the latest insights and what it means for patients and the industry.

7 min read

🔗Keep exploring

Foundayo Tracker
→
Foundayo vs Wegovy
→
Orforglipron Guide
→
All Guides
→
Start tracking